Table of Contents Table of Contents
Previous Page  681 / 812 Next Page
Information
Show Menu
Previous Page 681 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S677

4

Faculty of Pharmacy, University of Athens, Department of

Pharmacognosy and Natural Products Chemistry, Athens, Greece

5

GAIA Research Center, The Goulandris Natural History Museum,

Bioanalytical Department, Kifissia, Greece

Corresponding author.

Alzheimer’s disease (AD), a neurodegenerative neuropsychiatric

disorder, is often comorbid with depression and anxiety. Neu-

ropsychiatric disorders are also characterized by sex differences.

However, most preclinical pharmacological studies are conducted

using only males. Herein, we used male and female twelve-month-

old mice (3xTg) expressing mutated forms of human proteins Tau,

APP and Presenilin1. These mice are considered a valid animal

model of AD. We investigated the effects of the natural compound

trans-crocin-4 (TC-4), which is derived from Crocus sativus and

the olive compound oleuropein on the cognitive, depressive and

anxious profile of 3xTg mice. We found that male and female

3xTg mice exhibited reduced locomotor activity and oleuropeine

treatment (100mg/kg i.p., for 21 days) did not reverse this pheno-

type. In addition, anxiety- and depressive-like behaviors were not

affected by genotype, sex or oleuropeine treatment. Interestingly,

oleuropeine exhibited a tendency to enhance cognitive perfor-

mance in male 3xTg mice. Treatment with TC-4 (50 and 150mg/kg,

i.p., acutely or chronically for 10 days) affected locomotor activ-

ity in a sex-differentiated manner. Interestingly, acute TC-4 clearly

enhanced cognitive performance in all groups although it reduced

center entries in the open field. Additionally, chronic TC-4 treat-

ment enhanced novel object discrimination mainly in male 3xTg

mice. Our findings highlight the potential of those natural com-

pounds, which warrant further investigation but also emphasize

the benefits of including both males and females in preclinical

pharmacological studies.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2010

EV1026

A comparison of risperidone and

olanzapine in the acute treatment of

persistent delusional disorder: Data

from a retrospective chart review

K. Kulkarni

1 ,

, R. Arasappa

1

, K. Prasad

1

, A. Zutshi

2

, P. Chand

1

,

K. Muralidharan

1

, P. Murthy

1

1

National Institute of Mental Health & Neurosciences, Psychiatry,

Bangalore, India

2

Epworth Hospital, Psychiatry, Melbourne, Australia

Corresponding author.

Introduction

There is a lack of pharmacological trials studying

drug response in Persistent Delusional Disorder (PDD) to guide clin-

ical practice. Available reviews of retrospective data indicate good

response to second-generation antipsychotics, but even such data

from India is sparse.

Objectives and aims

We aimed to compare the response of acute

PDD to risperidone and olanzapine in our retrospective review.

Methods

We conducted a retrospective chart review of patients

diagnosed with PDD (ICD-10) from 2000 to 2014 (

n

= 455) at our

Center. We selected the data of patients prescribed either olanzap-

ine or risperidone for the purpose of this

analysis.We

extracteddata

about dose, drug compliance and response, adverse effects, number

of follow-up visits and hospitalizations. The study was approved by

the Institute Ethics Committee.

Results

A total of 280/455 (61%) were prescribed risperidone and

86/455 (19%) olanzapine. The remaining (

n

= 89; 20%) had received

other antipsychotics. The two groups were comparable in socio-

demographic and clinical characteristics of PDD. Compliance was

good and comparable in both groups (> 80%,

P

= 0.2). Response to

treatment was comparable in both groups (85% partial response

and > 52% good response, all

P

> 0.3). Olanzapine was effective at

lower mean chlorpromazine equivalents than risperidone (240 vs.

391,

P

< 0.05).

Conclusion

Our study indicates a good response to both risperi-

done and olanzapine, if compliance to treatment can be ensured.

In the absence of specific treatment guidelines for PDD, second-

generation antipsychotics like risperidone and olanzapine offer

good treatment options for this infrequently encountered and dif-

ficult to treat psychiatric disorder.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2011

EV1027

Effects of typical and atypical

antipsychotics on spontaneous

neuronal network activity in vitro

C. Lange-Asschenfeldt

, U. Henning , P. Görtz

Heinrich-Heine-University Duesseldorf, Psychiatry and

Psychotherapy, Duesseldorf, Germany

Corresponding author.

Introduction

Microelectrode arrays (MEAs) with cultured neu-

ronal networks are highly suitable to quantify neuroactive activity

and neurotoxicity of applied substances.

Objective

Multiparametric characterization of functional alter-

ations of in vitro-neuronal network activity by different typical and

atypical antipsychotics.

Aims

To identify differential effects of antipsychotics on sponta-

neous neuronal network activity as a functional readout.

Methods

Cultured networks of dissociated cortical cells of post-

partal mice coupled to MEAs were exposed to increasing doses

of aripiprazole, clozapine, haloperidol, olanzapine, raclopride, and

risperidone.

Results

We found a concentration-dependent inhibition of firing

patterns for all substances except olanzapine. All other substances

mediated a concomitant irreversible suppression of burst and spike

rates, a decrease of the burst duration and the number of spikes

in bursts as well as dose-dependent network desynchronization

(decrease of Cohen’s kappa). The comparison of the different

antipsychotics with regard to their half-maximal effective dose

values (EC-50) for inhibiting the spike rate yielded an increas-

ing order of EC

50

values, i.e. a declining order of toxic potency,

of aripiprazole (8.77 M) < clozapine (9.36 M) < haloperidol

(9.77 M) < risperidone (15.9 M) < raclopride (22.7 M). No sig-

nificant correlations were identified between EC

50

values of the

distinct antipsychotics and their binding affinity to the dopamine

D(2), the serotonin 5-HT(1A), 5-HT(2A), 5-HT(2C), and the M(1)

and M(2) muscarinic acetylcholine receptors.

Conclusion

In MEAs, a dose-dependent neurotoxic effect of typ-

ical and atypical antipsychotics alike occurred at supratherapeutic

doses via a yet unknown mechanism that did not involve actions

on major receptor targets of these compounds.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2012

EV1028

Increased libido as a buproion-SR side

effect: Clinical description of a case

L. Gallardo Borge

, C. Noval Canga , L. Rodíguez Andrés ,

I. Sevillano Benito , M. Hernández García , A. Álvarez Astorga ,

R. Hernández Antón , S. Gómez Sánchez , G. Isidro García ,

P. Marqués Cabezas

Hospital Clínico Universitario, Servicio de Psiquiatría, Valladolid,

Spain

Corresponding author.